Skip to content

Study · Non-randomized trial · 2016

3 results

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.

Ahrén B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H

Diabetes therapy : research, treatment and education of diabetes and related disorders18 Jun 2016Cited by 4 (Europe PMC)

PMID27319011 (opens in a new tab)PMCIDPMC5014785 (opens in a new tab)DOI10.1007/s13300-016-0179-6 (opens in a new tab)PepBankPUB-27319011
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide reduced 2-h postprandial glucagon at Week 24 versus placebo (P < 0.00001).

    In plain wordsIn patients with diabetes, lixisenatide reduced postmeal glucagon compared with placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucagon at Week 24
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001).
    2 context sentences
    Summary · context
    A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin).
    Summary · context
    Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c.
  2. 02HumanObservational studyMechanism

    In lixisenatide-treated patients with type 2 diabetes, postprandial glucagon change correlated with postprandial glucose reductions (P < 0.00001).

    In plain wordsIn lixisenatide-treated patients with diabetes, postmeal glucagon reduction was linked to postmeal glucose reduction.

    Peptide
    Lixisenatide
    Outcome
    Not applicableGlucagon change correlation with postprandial glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001).
    2 context sentences
    Summary · context
    A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin).
    Summary · context
    Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c.
  3. 03HumanObservational studyMechanism

    In lixisenatide-treated patients with type 2 diabetes, postprandial glucagon change correlated with HbA1c reductions (P < 0.00001).

    In plain wordsIn lixisenatide-treated patients with diabetes, postmeal glucagon reduction was linked to HbA1c reduction.

    Peptide
    Lixisenatide
    Outcome
    Not applicableGlucagon change correlation with HbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001).
    2 context sentences
    Summary · context
    A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin).
    Summary · context
    Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00713830

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

Sanofin = 859Jul 2008 to Jan 2011

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 14 Dec 2016
CompletedPhase 3Results postedNCT00712673

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Sanofin = 680Jun 2008 to Mar 2011

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 15 Dec 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.